Atherothrombosis and Coronary Artery Disease
Integrated basic and clinical research to study the etiology, pathogenesis, prevention, diagnosis, and treatment of CAD and atherothrombosis; translation of promising scientific and technological advances from discovery through preclinical studies to networks and multisite clinical trials.
Program Officers
Yves Rosenberg, M.D., M.P.H.
Branch Chief, Coronary artery disease; Single and multisite clinical trials
301-435-1292
Jue Chen, M.B., M.S., Ph.D.
Acting Deputy Branch Chief, Aging biology; Pharmacology and toxicology
301-435-0532
Jerome Fleg, M.D.
Clinical cardiovascular disease; Exercise physiology
301-435-0420
Ahmed A.K. Hasan, M.D., Ph.D.
Pharmacogenomics; Functional genomics; Inflammation; Anti-thrombotic agents
301-435-0064
Ruth Kirby, R.N., B.S.
Clinical trial management/operations; Autoimmune and cardiovascular diseases
301-435-0401
Martin Playford, Ph.D.
Inflammation; Translational research; Cell and molecular biology
301-827-3716
David Schopfer, M.D., M.A.S.
Clinical cardiovascular disease; Coronary artery disease
301-402-3833